As discussed in more detail below, CerS6-dependent C16:0 ceramide production is increased in specific tissues during obesity development, and transgenic expression of CerS6 in primary hepatocytes is sufficient to inhibit insulin-stimulated phosphorylation of AKT [27, 93]. The gene discussed is AKT1; the disease is obesity disorder.